12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TCN-202: Phase I data

Top-line data from a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial in 40 healthy volunteers showed that IV TCN-202 was well tolerated with no dose-limiting toxicities (DLTs) or serious adverse events reported. No antibodies...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >